Cardiovascular Systems, Inc. – Value Analysis (NASDAQ:CSII) : August 15, 2017

Capitalcube gives Cardiovascular Systems, Inc. a score of 29.

Our analysis is based on comparing Cardiovascular Systems, Inc. with the following peers – AngioDynamics, Inc., LeMaitre Vascular, Inc., Endologix, Inc., Boston Scientific Corporation, Merit Medical Systems, Inc., Medtronic plc and Johnson & Johnson (ANGO-US, LMAT-US, ELGX-US, BSX-US, MMSI-US, MDT-US and JNJ-US).

Investment Outlook

Cardiovascular Systems, Inc. has a fundamental score of 29 and has a relative valuation of OVERVALUED.

Fundamental Score

Access our research and ratings on Cardiovascular Systems, Inc.

Company Overview

  • With respect to peers, relative outperformance over the last year is in contrast to the more recent underperformance.
  • It currently trades at a Price/Book ratio of (8.52).
  • CSII-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • CSII-US has relatively low net profit margins while its asset efficiency is relatively high.
  • The company’s year-on-year change in revenues and earnings are better than the median among its peer group.
  • CSII-US‘s return on assets currently and over the past five years has trailed the peer median and suggests the company might be operationally challenged relative to its peers.
  • Company appears to give away relatively high gross margins to relatively high operating costs suggesting a differentiated product portfolio with low pre-tax margins relative to peers.
  • CSII-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful for an analysis between historical growth (using annualized three-year revenue growth) and investor growth expectations (as suggested by P/E or Price/EBITDA) .
  • The company’s relatively low level of capital investment and below peer median returns on capital suggest that the company is in maintenance mode.

Access our research and ratings on Cardiovascular Systems, Inc.

Leverage & Liquidity

  • Of the 7 chosen peers for the company, only 6 of the stocks have an outstanding debt balance. Companies with no debt include LMAT-US.

CSII-US has moved to a Constrained from an Quick & Able profile at the prior year-end.

Access the detailed analysis for Cardiovascular Systems, Inc.

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
AngioDynamics, Inc. 15.97 2.15 8.88 28.37
LeMaitre Vascular, Inc. 0 7.25 1166.86 999
Endologix, Inc. 44.05 2.82 -2.95 -21.58
Boston Scientific Corporation 13.45 0.75 5.87 17.49
Merit Medical Systems, Inc. 11.44 2.57 3.75 30.65
Medtronic plc 25.02 1.75 5.91 20.84
Johnson & Johnson 9.17 1.34 27.52 61.86
Cardiovascular Systems, Inc. N/A 4.26 0 N/A
Peer Median 13.45 2.36 5.91 28.37
Best In Class 9.17 7.25 1166.86 999

Looking for more metrics and analysis for Cardiovascular Systems, Inc.?

Company Profile

Cardiovascular Systems, Inc. is a medical device company, which develops and sells devices for treating cardiovascular diseases. It focuses on developing and commercializing minimally invasive treatment solutions for vascular diseases. The company’s products such as diamondback 360° PAD system and the stealth 360° PAD system are catheter based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee. The company was founded in 2000 and is headquartered in St. Paul, MN.


The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website